Tobias Reichmuth – the longevity market starts now

Dr Tobias Reichmuth talks taking hardcore science to market without biotech approval risk and the catalyst that is translational research.

We were lucky enough to attend the?Longevity Investors Conference?last month; this key event attracts those interested in learning about longevity investment opportunities and finding out more about the exciting directions in which the field is accelerating. To put it succinctly, as?MIT Tech Review did recently, LIC “brings academic scientists and biotech companies together with deep-pocketed investors. We’re talking millionaires and billionaires.”

My take on this: One of the driving forces behind the Longevity Investors Conference is Dr Tobias Reichmuth; a company-builder since the age of 21, Reichmuth has invested in more than 20 startups and is one of the founding partners of?Maximon, the longevity company building. Along with his Maximon colleague Marc P Bernegger, Reichmuth launched the Longevity Investors Conference, and we couldn’t pass up the chance to grab some time with him to?discuss the current longevity market.

Tobias Reichmuth on…

Longevity investments and interventions – now is the right time

When it comes to longevity, I would say the market starts now. Of course, you can do a lot of things for your longevity, but what we see now is translational research being put into products and companies. So both from a consumer, but also from an investor perspective, I think it’s the right time to start with longevity – investments and interventions.

Watch the video HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!